Cencora (COR) is back in focus after a busy stretch, with quarterly results, a new segment structure, fresh bond issuance and a cluster of analyst rating changes all landing at once.

At a share price of $351.06, Cencora has recently seen a 4.0% one day decline and a softer 90 day share price return of a 3.01% decline. Its 1 year total shareholder return of 44.92% and 5 year total shareholder return of 251.63% indicate that longer term momentum has been strong as investors respond to acquisitions, the new reporting structure and the recent bond issuance.

If activity around Cencora has you thinking about where else capital is moving, it could be a good moment to scan 24 healthcare AI stocks as a starting list of potential ideas.

So with Cencora trading at $351.06, a headline intrinsic discount of about 42% and analyst targets sitting higher, is the recent pullback giving you an entry point, or is the market already baking in the next leg of growth?

Most Popular Narrative: 12.2% Undervalued

With Cencora last closing at $351.06 and the most followed fair value estimate sitting at $399.80, the narrative is building in a meaningful upside gap that depends on how earnings, margins and valuation multiples evolve from here.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to respond to the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act. These efforts aim to improve supply chain efficiency and transparency, which could support higher net margins and operating income over time.

Read the complete narrative. Read the complete narrative.

Want to see what is underneath that near $400 fair value tag? The narrative focuses on steady revenue trends, potential margin uplift and a richer future earnings multiple. Curious how those three elements might fit together over the next few years, and what kind of profit profile they could imply by the late 2020s?

Result: Fair Value of $399.80 (UNDERVALUED)

However, you also need to weigh risks such as pressure from biosimilars and generics, as well as tougher policy and regulatory scrutiny that could squeeze margins and earnings.

Another View: Earnings Multiple Sends a Different Signal

Our earlier fair value discussion points to Cencora trading at a discount, but the earnings multiple tells a different story. At a P/E of 42x versus the US Healthcare average of 23.5x and a fair ratio of 34.9x, the stock screens as expensive. Could that premium shrink if sentiment cools?

See what the numbers say about this price in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own Cencora Narrative

If you see the data differently or simply prefer to reach your own view, you can build a tailored Cencora story in just a few minutes: Do it your way

A great starting point for your Cencora research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop at just one company, you could miss out on opportunities that better match your style, so use the Simply Wall St Screener to widen your field of choices.

• Spot potential value opportunities early by scanning our list of 55 high quality undervalued stocks chosen using both quality and valuation filters.
• Prioritize resilience by checking companies in the 85 resilient stocks with low risk scores that score well on our risk checks and financial strength metrics.
• Hunt for less crowded ideas with the screener containing 23 high quality undiscovered gems that highlight companies with strong fundamentals but lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.